FMP
Vyant Bio, Inc.
VYNT
NASDAQ
Inactive Equity
Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). Vyant Bio, Inc. has a collaboration agreement to discover drugs for the treatment of Parkinson's Disease. The company is based in Cherry Hill, New Jersey.
0.194 USD
0.014 (7.22%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Mr. Andrew D.C. LaFrence CPA
sector
Healthcare
industry
Biotechnology
website
https://www.vyantbio.comexchange
NASDAQ
Description
Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). Vyant Bio, Inc. has a collaboration agreement to discover drugs for the treatment of Parkinson's Disease. The company is based in Cherry Hill, New Jersey.
CIK
0001349929
ISIN
US92942V2088
CUSIP
92942V109
Address
2 Executive Campus
Phone
201 479 1357
Country
US
Employee
4
IPO Date
Apr 1, 2021
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
VYNT Financial Summary
CIK
0001349929
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
92942V109
ISIN
US92942V2088
Country
US
Price
0.19
Beta
0.56
Volume Avg.
17.86k
Market Cap
0
Shares
-
52-Week
0.141-1.58
DCF
5.96
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.07
P/B
-
Website
https://www.vyantbio.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest VYNT News
It looks like there's no news available.
